Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Innodata Q1 2026 Earnings Call - Record Revenue and Margin Expansion on AI Data and Agentic AI Platform Breakthroughs
Innodata delivered a record first quarter of 2026, with revenue surging 54% year-over-year to $90.1 million, adjusted EBITDA jumping 96% to $25 million, and adjusted gross margins expanding 6 percenta...
- Revenue reached a record $90.1 million, up 54% year-over-year and 24% sequentially, significantly exceeding analyst consensus by approximately $13.6 million or 18%.
- Adjusted EBITDA surged 96% year-over-year to $25 million, representing a 28% margin and beating analyst estimates by an extraordinary 139%.
- Adjusted gross margins expanded by 6 percentage points to 47%, marking a 7-point improvement over the company's previously stated 40% public target.
- +7 more takeaways
Xenon Pharmaceuticals Q1 2026 Earnings Call - Azetukalner NDA Filing on Track for Q3 2026 as $750M Financing Secures Runway to 2029
Xenon Pharmaceuticals reported strong operational progress in Q1 2026, anchored by positive Phase III X-TOLE2 data for azetukalner (AZK) in focal onset seizures, which exceeded expectations and demons...
- Xenon Pharmaceuticals completed a $747.5 million public offering in Q1 2026, raising cash to $1.3 billion and extending its operating runway into 2029, providing ample capital for the AZK launch and pipeline advancement.
- The Phase III X-TOLE2 study for azetukalner (AZK) in focal onset seizures met its primary endpoint with a 53.2% reduction in monthly seizure frequency at 25 mg, exceeding Phase II-B results and demonstrating rapid onset of action without titration.
- Xenon targets an NDA submission to the FDA in Q3 2026, with a base-case expectation of approval in late 2027 or early 2028, assuming a standard 12-month review and 3-month DEA scheduling period.
- +7 more takeaways
Comstock Inc. Q1 2026 Earnings Call - Transition from Balance Sheet Repair to Operational Execution at Scale
Comstock Inc. is shifting from a phase of balance sheet recapitalization to operational execution, marking a pivotal moment for the company. The first quarter of 2026 saw the completion of a $57.5 mil...
- Comstock completed a $57.5 million oversubscribed equity financing, leaving a cash balance of over $53 million and eliminating all legacy debt, significantly strengthening its balance sheet.
- The company is transitioning from balance sheet repair to operational execution, with its first solar panel recycling facility in Silver Springs, Nevada, nearing completion and scheduled for commercial operations in June.
- Comstock plans to monetize all remaining mining assets, with a definitive agreement expected in Q3 2026, which will simplify the company, reduce annual cash spending by up to $1.5 million, and provide cash for redeployment.
- +7 more takeaways
Natera Q1 2026 Earnings Call - Record MRD Volumes and Japan Launch Drive Revenue Reset
Natera reported a record Q1 2026 with revenues of $697 million, reflecting 39% year-over-year growth and a milestone of over 1 million units processed in a single quarter. The company's clinical MRD b...
- 1. Natera reported Q1 2026 revenues of $697 million, a 39% year-over-year increase, marking a significant acceleration in growth at scale.
- 2. The company processed over 1 million units in a single quarter for the first time, with Signatera clinical MRD volume hitting a record 249,000 tests, up 55% year-over-year.
- 3. Management reset the full-year revenue guidance upward by $120 million at the midpoint, reflecting strong volume momentum and realized ASP growth.
- +12 more takeaways
Crinetics Pharmaceuticals Q1 2026 Earnings Call - PALSONIFY Launch Momentum Accelerates With 232 New Patient Enrollments
Crinetics Pharmaceuticals delivered a strong first quarter 2026, driven by the accelerating launch of PALSONIFY for acromegaly. The company enrolled 232 new patients, generated $10.3 million in net pr...
- PALSONIFY generated $10.3 million in net product revenue in Q1 2026, with total company revenue reaching $10.7 million including $0.4 million from a Japanese licensing deal.
- The company enrolled 232 new patients on PALSONIFY during the quarter, demonstrating consistent weekly growth and expanding beyond early adopters.
- Treatment-naive patients now account for 15% of new PALSONIFY enrollments, up from 5% in Q4 2025, signaling growing physician confidence in first-line use.
- +7 more takeaways
Myomo Q1 2026 Earnings Call - Recurring Revenue Shift Accelerates as O&P Partnerships and Payer Contracts Expand Market Access
Myomo delivered a disciplined Q1 2026 that confirmed its pivot toward recurring patient sources and stronger unit economics. Revenue rose 3% to $10.1 million, driven by a 9% increase in average sellin...
- Q1 2026 revenue reached $10.1 million, up 3% year-over-year, driven by a 9% increase in average selling price to $58,800 from Medicare fee updates and a favorable payer mix.
- Gross margin expanded 100 basis points to 68.2%, while operating expenses declined 1% to $10.1 million, resulting in a 20% improvement in adjusted EBITDA.
- Recurring patient sources now account for 49% of revenue, up from 25% in Q1 2025, signaling a successful shift away from high-cost direct-to-consumer advertising.
- +7 more takeaways
AvePoint Q1 2026 Earnings Call - AI Governance Becomes the Enterprise Trust Layer
AvePoint delivered a strong start to 2026 with Q1 revenue of $117.2 million, beating guidance on both top and bottom lines. The company reported 26% year-over-year revenue growth and 35% SaaS revenue ...
- Total Q1 revenue reached $117.2 million, reflecting 26% year-over-year growth and exceeding the high end of guidance.
- SaaS revenues grew 35% year-over-year to $93.4 million, now representing 80% of total revenue.
- ARR closed at $435.2 million, up 26% year-over-year, marking the 12th consecutive quarter of double-digit organic net new ARR growth.
- +7 more takeaways
ICF International Q1 2026 Earnings Call - Federal Stabilization and AI Resilience Fuel Growth Outlook
ICF International reported a solid start to 2026, with Q1 revenues declining 10.3% year-over-year to $437.5 million due to timing shifts in commercial energy and international government contracts rat...
- Q1 2026 total revenue declined 10.3% year-over-year to $437.5 million, primarily due to $12 million in revenue timing shifts in commercial energy and international government contracts rather than fundamental demand issues.
- Federal government revenues stabilized with an 8.6% sequential increase to $182.3 million, signaling recovery after last year's volatility and aligning with expectations for year-over-year growth by Q4 2026.
- International government revenues surged 17.5% year-over-year, driven by significant contract wins from European Union and U.K. clients, with strong momentum expected to continue through the year.
- +7 more takeaways
McKesson Corporation Q4 2026 Earnings Call - Oncology Growth & MSO Separation Drive 18% EPS Expansion
McKesson closed fiscal 2026 with a commanding 18% jump in adjusted EPS to $39.11, powered by a $403 billion revenue top line and relentless execution across its growth pillars. The company’s Oncology ...
- Full-year adjusted EPS expanded 18% to $39.11, outpacing long-term growth targets of 13%-16%.
- Consolidated revenue reached $403 billion, a 12% year-over-year increase driven by broad-based demand.
- Oncology and Multispecialty segment revenue surged 35% to $12.7 billion, fueled by PRISM Vision and Core Ventures acquisitions.
- +7 more takeaways
Genpact Q1 2026 Earnings Call - Agentic Solutions Double Contract Value, Revenue Hits Record $1.3 Billion
Genpact delivered a record Q1 2026, driven by a sharp pivot toward agentic and advanced technology solutions that now account for 27% of total revenue. Advanced Technology Solutions grew 24% year-over...
- Record Q1 2026 Revenue: Total revenue grew 6.7% year-over-year to $1.296 billion, marking a strong start to the fiscal year.
- Agentic Solutions Momentum: Contract value for agentic solutions nearly doubled from all of 2025, with more than 50% of cumulative awarded contract value coming from new clients.
- Advanced Technology Solutions Acceleration: Advanced Technology Solutions revenue grew 24% year-over-year to $345 million, now representing 27% of total revenue.
- +7 more takeaways